Valérie Cochen De Cock1,2. 1. Sleep and Neurology unit, Beau Soleil Clinic, 119 avenue de Lodève, 34070, Montpellier, France. valerie.cochen@gmail.com. 2. EuroMov, Université de Montpellier, Montpellier, France. valerie.cochen@gmail.com.
Abstract
PURPOSE OF REVIEW: The aim of this article was to review the options and particularities of the treatment of restless legs syndrome (RLS) in Parkinson's disease (PD). RECENT FINDINGS: RLS is more frequent in PD than in the general population. Even if these two disorders share some specificity (dopa-sensitivity), they also differ in many features (iron load, genetic profile, dopaminergic cell count), resulting in different adaptations of the treatment. Only one study has specifically explored and demonstrated the efficacy of a treatment (rotigotine) in RLS with PD, constraining us to treat RLS with PD by analogy as idiopathic RLS in the other cases. However, arrangements linked to the peculiar population and pathology of PD are required. The treatment of RLS in PD consists in adaptation of dopaminergic treatment and introduction of alpha-2-delta ligands and, in refractory cases, of opioids or deep brain stimulation. Iron deficiency should probably not be compensated.
PURPOSE OF REVIEW: The aim of this article was to review the options and particularities of the treatment of restless legs syndrome (RLS) in Parkinson's disease (PD). RECENT FINDINGS:RLS is more frequent in PD than in the general population. Even if these two disorders share some specificity (dopa-sensitivity), they also differ in many features (iron load, genetic profile, dopaminergic cell count), resulting in different adaptations of the treatment. Only one study has specifically explored and demonstrated the efficacy of a treatment (rotigotine) in RLS with PD, constraining us to treat RLS with PD by analogy as idiopathic RLS in the other cases. However, arrangements linked to the peculiar population and pathology of PD are required. The treatment of RLS in PD consists in adaptation of dopaminergic treatment and introduction of alpha-2-delta ligands and, in refractory cases, of opioids or deep brain stimulation. Iron deficiency should probably not be compensated.
Entities:
Keywords:
Alpha-2-delta ligands; Deep brain stimulation; Dopamine agonists; Iron; Opioids; Parkinson’s disease; Periodic limb movements; Restless legs syndrome
Authors: Isaac Shpirer; Ala Miniovitz; Colin Klein; Richard Goldstein; Tatiana Prokhorov; Jack Theitler; Lea Pollak; Jose Martin Rabey Journal: Mov Disord Date: 2006-09 Impact factor: 10.338
Authors: Richard K Bogan; Michel A Cramer Bornemann; Clete A Kushida; Pierre V Trân; Ronald W Barrett Journal: Mayo Clin Proc Date: 2010-06 Impact factor: 7.616
Authors: Claudia Trenkwalder; K Ray Chaudhuri; Pablo Martinez-Martin; Olivier Rascol; Reinhard Ehret; Martin Vališ; Maria Sátori; Anna Krygowska-Wajs; Maria J Marti; Karen Reimer; Alexander Oksche; Mark Lomax; Julia DeCesare; Michael Hopp Journal: Lancet Neurol Date: 2015-10-19 Impact factor: 44.182
Authors: James R Connor; Xin-Sheng Wang; Richard P Allen; John L Beard; Jason A Wiesinger; Barbara T Felt; Christopher J Earley Journal: Brain Date: 2009-05-25 Impact factor: 13.501
Authors: Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Krystyna Honczarenko; Peter Dioszeghy; Dennis Hill; Tim Anderson; Vilho Myllyla; Jan Kassubek; Malcolm Steiger; Marco Zucconi; Eduardo Tolosa; Werner Poewe; Erwin Surmann; John Whitesides; Babak Boroojerdi; Kallol Ray Chaudhuri Journal: Mov Disord Date: 2010-11-18 Impact factor: 10.338